223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma.
Salivary duct carcinoma (SDC) is a rare malignancy, frequently overexpressing androgen receptor (AR). Therefore, similar to AR-positive prostate cancer (PCa), AR-positive SDC patients benefit from androgen deprivation therapy and, after progression on ADT, might take advantage of Ra dichloride, a radiopharmaceutical approved for the treatment of castration-resistant PCa with symptomatic bone disease. We report the case of a 75-year-old man with castration-resistant SDC and osteoblastic bone metastases who, after Ra treatment, achieved adequate control of bone pain and bone lesion reduction with minor side effects. Evaluation of this strategy in other patients with similar characteristics is warranted.
From the *Nuclear Medicine Unit, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin; †Department of Medical Oncology 2, Città della Salute e della Scienza Hospital, Turin; and ‡Division of Medical Oncology, Department of Oncology, University of Turin San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
Matteo
M
Manfredi
Mario
M
Airoldi
Marcello
M
Tucci
Consuelo
C
Buttigliero
Antonella
A
Parente
Tiziana
T
Angusti
D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D044584:Carcinoma, Ductal / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011883:Radium / Q000627:therapeutic use*; D012468:Salivary Gland Neoplasms / Q000473:pathology* / Q000532:radiotherapy
D019275:Radiopharmaceuticals; D011883:Radium